Last reviewed · How we verify

Acetylsalicylic morning

Basque Health Service · Phase 3 active Small molecule

Acetylsalicylic morning is a Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Small molecule drug developed by Basque Health Service. It is currently in Phase 3 development for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Pain and fever management. Also known as: Asa, Low dose, aspirine.

Acetylsalicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects.

Acetylsalicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects. Used for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Pain and fever management.

At a glance

Generic nameAcetylsalicylic morning
Also known asAsa, Low dose, aspirine
SponsorBasque Health Service
Drug classNonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent
TargetCyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaCardiovascular; Pain management; Inflammation
PhasePhase 3

Mechanism of action

Acetylsalicylic acid (aspirin) acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This reduces synthesis of prostaglandins (involved in inflammation and pain) and thromboxane A2 (a platelet aggregator), resulting in anti-inflammatory, pain-relieving, and blood-thinning effects. The antiplatelet effect is particularly durable because it affects long-lived platelets that cannot synthesize new COX-1.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Acetylsalicylic morning

What is Acetylsalicylic morning?

Acetylsalicylic morning is a Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent drug developed by Basque Health Service, indicated for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Pain and fever management.

How does Acetylsalicylic morning work?

Acetylsalicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects.

What is Acetylsalicylic morning used for?

Acetylsalicylic morning is indicated for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Pain and fever management, Inflammatory conditions.

Who makes Acetylsalicylic morning?

Acetylsalicylic morning is developed by Basque Health Service (see full Basque Health Service pipeline at /company/basque-health-service).

Is Acetylsalicylic morning also known as anything else?

Acetylsalicylic morning is also known as Asa, Low dose, aspirine.

What drug class is Acetylsalicylic morning in?

Acetylsalicylic morning belongs to the Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent class. See all Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid-antiplatelet-agent.

What development phase is Acetylsalicylic morning in?

Acetylsalicylic morning is in Phase 3.

What are the side effects of Acetylsalicylic morning?

Common side effects of Acetylsalicylic morning include Gastrointestinal bleeding or ulceration, Dyspepsia, Nausea, Increased bleeding risk, Hypersensitivity reactions.

What does Acetylsalicylic morning target?

Acetylsalicylic morning targets Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) and is a Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent.

Related